Literature DB >> 3177430

Antimalarial drugs and pregnancy.

A Parke1.   

Abstract

The use of chloroquine and hydroxychloroquine during pregnancy is controversial. These 4-aminoquinoline drugs cross the placenta and have been reported to cause fetal abnormalities, including loss of vision, ototoxicity, and cochleovestibular dysfunction. However, other reports suggest that 4-aminoquinoline drugs can be taken safely during pregnancy, even in dosages used to control systemic connective tissue diseases. We retrospectively studied eight patients who took antimalarial drugs continuously throughout pregnancy. There was a total of 14 pregnancies in women receiving these drugs; three occurred during periods of disease activity and all of these resulted in failure to complete pregnancy successfully. Of the remaining 11 pregnancies exposed to antimalarial drugs, one resulted in stillbirth; four resulted in spontaneous abortion; and six had normal full-term standard deliveries. None of the live births demonstrated any congenital abnormalities. Hence, it is possible for women to produce normal live babies despite taking large doses of these drugs. If patients with systemic lupus erythematosus are already taking antimalarial drugs when they become pregnant, it is believed that the risk of disease flare and loss of pregnancy from discontinuing therapy outweighs any risks to fetuses from continuing the medication.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3177430     DOI: 10.1016/0002-9343(88)90359-2

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  8 in total

Review 1.  The role of antimalarial agents in the treatment of SLE and lupus nephritis.

Authors:  Senq-J Lee; Earl Silverman; Joanne M Bargman
Journal:  Nat Rev Nephrol       Date:  2011-10-18       Impact factor: 28.314

Review 2.  The safety of antimalarial drugs in pregnancy.

Authors:  P A Phillips-Howard; D Wood
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

3.  Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression.

Authors:  Xiao-Xuan Wu; Seth Guller; Jacob H Rand
Journal:  Am J Obstet Gynecol       Date:  2011-06-24       Impact factor: 8.661

Review 4.  New insights into mechanisms of therapeutic effects of antimalarial agents in SLE.

Authors:  Daniel J Wallace; Vineet S Gudsoorkar; Michael H Weisman; Swamy R Venuturupalli
Journal:  Nat Rev Rheumatol       Date:  2012-07-17       Impact factor: 20.543

5.  Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases.

Authors:  N M Buchanan; E Toubi; M A Khamashta; F Lima; S Kerslake; G R Hughes
Journal:  Ann Rheum Dis       Date:  1996-07       Impact factor: 19.103

Review 6.  Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications.

Authors:  S Krishna; N J White
Journal:  Clin Pharmacokinet       Date:  1996-04       Impact factor: 6.447

Review 7.  Adverse effects of antimalarials. An update.

Authors:  G A Luzzi; T E Peto
Journal:  Drug Saf       Date:  1993-04       Impact factor: 5.606

8.  Hearing of neonates without risk indicators for hearing loss and use of antimalarial drugs during pregnancy: a historical cohort study in the Northern Region of Brazil.

Authors:  Fernanda Soares Aurélio Patatt; André Luiz Lopes Sampaio; Pedro Luiz Tauil; Carlos Augusto Costa Pires de Oliveira
Journal:  Braz J Otorhinolaryngol       Date:  2019-07-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.